Can a 2‑month‑old infant acquire rotavirus if the mother is being treated with Ocrevus (ocrelizumab)?

Can a 2-Month-Old Infant Acquire Rotavirus if the Mother is Treated with Ocrevus?

Yes, a 2-month-old infant can absolutely acquire rotavirus infection regardless of maternal Ocrevus treatment—the mother's immunosuppression does not directly prevent the infant from getting rotavirus, and the infant should receive rotavirus vaccination on schedule starting at 2 months of age.

Understanding the Clinical Context

The question conflates two separate issues: (1) whether maternal Ocrevus treatment affects infant susceptibility to rotavirus infection, and (2) whether infants exposed to maternal Ocrevus can safely receive rotavirus vaccination. Let me address both:

Infant Susceptibility to Rotavirus

Infants at 2 months of age are highly susceptible to rotavirus gastroenteritis. Research demonstrates that 27% of all rotavirus cases occur in infants under 6 months of age, with the highest number of episodes per month of age (6% of all cases) occurring during the second month of life 1. This contradicts the traditional assumption that young infants are protected by maternal antibodies—they are not adequately protected and represent a vulnerable population.

Maternal Ocrevus (ocrelizumab) treatment causes B-cell depletion in the mother, which theoretically could reduce transplacental transfer of protective antibodies. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to anti-CD20 antibodies during pregnancy 2. Despite this, there is no evidence that these infants have increased susceptibility to rotavirus specifically—they simply need appropriate vaccination.

Rotavirus Vaccination in Exposed Infants

The critical clinical decision is whether to vaccinate the infant, not whether they can "get" rotavirus (they can and will be exposed regardless).

Vaccination Timing and Safety

The AAP recommends that rotavirus vaccine should be administered starting at 2 months of age, with the first dose given between 6 weeks and 14 weeks, 6 days of age 3. For infants exposed to maternal immunosuppressive therapy:

• Do not administer live or live-attenuated vaccines to infants born to mothers exposed to Ocrevus during pregnancy before confirming recovery of B-cell counts as measured by CD19+ B-cells 2
• The potential duration of B-cell depletion in such infants is unknown, and this increases risks from live vaccines 2

Evidence from Similar Immunosuppressive Exposures

Recent data provides reassuring context:

• Infants exposed in utero to anti-TNF drugs, vedolizumab, or ustekinumab mount adequate serological responses to vaccines, and no relevant adverse events for non-live inactivated vaccines have been reported 4
• Studies assessing live-attenuated vaccines in infants exposed to biologics in utero have not generally observed serious adverse events with rotavirus vaccination 4
• Safe administration of rotavirus vaccine has been documented in infants exposed to immunosuppressive drugs (prednisone, azathioprine, tacrolimus/cyclosporine) during gestation, with no differences in adverse events 5
• A detailed case report of an infant exposed to tofacitinib (a JAK inhibitor) in utero and during breastfeeding showed normal immunologic profile and uneventful live rotavirus vaccination 6

Ocrevus-Specific Data

Large-scale pregnancy outcome data for ocrelizumab shows that in utero exposure was not associated with increased risk of adverse pregnancy or infant outcomes 7. However, the FDA label explicitly states that B-cell levels in infants following maternal exposure to Ocrevus have not been studied in clinical trials 2.

Real-world data demonstrates that antenatal exposure to BRMDs (including anti-CD20 agents) was not associated with increased infection risk in the first year of life, but was linked to significantly reduced uptake of live-attenuated rotavirus vaccine 8. This suggests clinicians are appropriately cautious but may be overly restrictive.

Clinical Algorithm for This Infant

1. Check infant B-cell counts (CD19+ B-cells) before administering rotavirus vaccine

   • If B-cell counts are normal/recovered: Proceed with standard vaccination schedule 2
   • If B-cell counts remain depleted: Consider consultation with pediatric immunology

2. If B-cell assessment is not immediately available and the infant is approaching 14 weeks, 6 days of age (the maximum age for first dose):

   • Weigh the risk of missing the vaccination window against theoretical risks
   • Consider that rotavirus is the most common cause of severe gastroenteritis in infants, with unexpectedly high burden in very young infants 1
   • The evidence from similar biologics suggests safety 5, 4, 6

3. Non-live vaccines can be administered without B-cell count confirmation, though consider assessing vaccine immune responses with specialist consultation 2

Critical Caveats

• The window for rotavirus vaccination is narrow: First dose must be given by 14 weeks, 6 days; all doses by 8 months 3
• Delaying vaccination may result in the infant becoming ineligible, leaving them unprotected during peak vulnerability
• While serious complications with rotavirus vaccine in biologic-exposed infants are rare, fatal disseminated infections have occurred with BCG vaccine in anti-TNF-exposed infants 4—this underscores the importance of B-cell assessment specifically for live vaccines

Bottom Line

The infant can acquire rotavirus infection regardless of maternal treatment. The real question is whether to vaccinate, and the answer is: yes, but check B-cell counts first to ensure safety of the live vaccine. If B-cells have recovered, proceed with standard vaccination at 2 months. If assessment will cause delay beyond the vaccination window, the balance of evidence from similar biologics suggests proceeding is reasonable, ideally with specialist input.